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Abstract. In patients with metastatic malignant melano- 
ma the distribution patterns of radiolabelled lymphok- 
ine-activated killer (LAK) cells were investigated. Pe- 
ripheral mononuclear cells (PMC) were isolated from 
six patients. LAK cells were generated by culturing PMC 
in complete medium containing 1000 U interleukin (IL)- 
2/ml and labelled with indium 111 before retransfer. We 
obtained scans at 2.5, 24, 48 or 96 h after injection with 
a high resolution gamma-camera. Intravenously injected 
LAK cells distributed to the lungs, liver, spleen and bone 
marrow. External tumour detection of known lymph 
node and bone metastases was successful in four. It 
failed in one patient with a solitary lung metastasis and 
in another patient with subcutaneous metastases. Our 
results suggest hat LAK cells show tumour homing, 
providing a direct interaction between tumour and cyto- 
toxic cells. We conclude that PMC seem to retain their 
ability to migrate after IL-2 stimulation and 111in_label_ 
ling. This technique may be helpful for kinetics studies 
or external detection of metastases in patients with 
malignant melanoma. 
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In t roduct ion  
The co-culture of normal peripheral blood lymphocytes 
(PBL) with interleukin-2 (IL-2) results in the generation 
of cytotoxic cells having broad anti-tumour activity. 
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These lymphokine-activated killer (LAK) cells are capa- 
ble of destroying a variety of target cells, including cul- 
tured and fresh autologous solid tumours, allogeneic and 
xenogeneic tumour cells and leukaemic blasts. The cyto- 
toxic activity of LAK cells is not restricted to products 
of the major histocompatibility complex, and fresh un- 
cultured normal cells are, for the most part, resistant 
to LAK lysis (Grimm et al. 1982). 
Several clinical studies indicate that adoptive immu- 
notherapy with LAK cells (Rosenberg et al. 1987) or 
tumour-infiltrating lymphocytes (TIL) (Topalian et al. 
1988) and IL-2 can achieve consistent and reproducible 
anti-tumour effects. It is questionable whether this effect 
is mediated by indirect mechanisms such as the induction 
of other cytokines or direct cell-mediated cytotoxicity. 
More recently, the ability of TILs to traffic and localise 
at tumour sites was demonstrated after pretreatment 
with cyclophosphamide and IL-2 infusion (Fisher et al. 
1989). Previous efforts to traffic radiolabelled LAK cells 
in patients with cancer of various origins failed (Lotze 
et al. 1980; Mukherji et al. 1988), or they showed poor 
enrichment a the tumour site in comparison with specif- 
ically tumour antigen-sensitised killer cells (Mazumber 
et al. 1984). 
In the present study we report the results of in vivo 
localisation of LAK cells. Our observations indicate that 
LAK cells are capable of localising at tumour sites in 
patients with malignant melanoma. No immunosuppres- 
sion or additional IL-2 infusion is necessary for this lym- 
phocyte traffic. 
Pat ients  and  methods  
Patients. The protocol was approved by the Committee ofMedical 
Ethics of the Medical Faculty of the University of Wfirzburg. Pa- 
tients with malignant melanoma after giving written consent were 
eligible. Tumour sites included the lung, inguinal and axillary 
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lymph nodes, subcutaneous and bone metastasis. The tumour sites 
were documented by computed-tomography (CT) scan and ultra- 
sonic examination. Following LAK cell infusion, the metastasis 
was histologically confirmed in five of six patients. According to 
the clinical situations ome patients were included in a clinical 
trial using IL-2. 
Preparation of LAK cells and radiolabelling. Peripheral blood was 
sampled by vein puncture (160 ml) in five patients; in one patient 
peripheral blood mononuclear cells (PMC) were collected by leuca- 
pheresis (Haemonetics V 50). The flow rate was 60-70 ml/min, and 
during 4 h a blood volume of 10-12 1 was processed. 
After separation by Ficoll-Hypaque centrifugation, PMC were 
cultured at 0.5 x 10 6 cells/ml in complete medium (CM) consisting 
of RPMI 1640 plus 10% human serum, 100 U/ml penicillin, 100 U/ 
ml streptomycin, 50 I-tg/ml gentamycin and 1000 IU/ml IL-2 (Pro- 
leukin, Cetus) for 4 days at 37 ° C at a humidity of 5% CO2. After 
harvesting and washing three times PMC were incubated with 
7.5 MBq indium 111 oxine in 4 ml PBS for 15 min at 37 ° C. Viabi- 
lity was assessed by trypan blue dye exclusion. Labelling efficacy 
was calculated from the dose calibrator measurements of radioac- 
tivity of the cell suspension during incubation (total added activity) 
and after labelling (final activity)as follows: 
final activity (MBq) x 100. 
Labelling efficacy (%) = total added activity (MBq) 
Finally, cells were washed twice and transferred into 250 ml normal 
saline and re-transfused within 30 min without, additional IL-2 
or immunosuppressive agents. Prior to transfusion the labelled 
LAK cells were filtered by passing the cell suspension through 
a standard blood tubing set containing a 200-gm in-line filter. Static 
gamma-camera imaging was obtained at 2.5, 24 and 48 or 96 h 
using a gamma-camera (GE 400 AT ZS) equipped with a low- 
energy collimator. The window was centered over the 173 keV pho- 
topeak of 111In. Anterior and posterior chest, abdomen, pelvis 
and skull, which were known to be clinically involved, were imaged. 
Counts per pixel were calculated with the regions of interest tech- 
nique at tumour sites and compared with the corresponding unin- 
volved side. 
Results 
Six men with metastat ic  mal ignant  melanoma received 
1~ ~In-radiolabel led LAK cells. The amount  of  z ~ In  ac- 
t ivity per number  of  appl ied cells ranged f rom 0.67 to 
5.2 MBq/10 s cells and the total  infused activity, f rom 
4.8 to 6.5 MBq.  The data  o f  re-transfused cells, viabi l i ty 
and labell ing efficacy for all six pat ients are shown in 
Table 1. LAK cell injection was well to lerated.  Only in 
three pat ients were transient fever with a max imum of  
38.5 ° C and slight chills observed, leading to no specific 
treatment.  
Re-transfused cells d istr ibuted pr imar i ly  to the lungs, 
spleen and liver with min imal  uptake in bone. After  24 h 
the liver and spleen showed a sl ight increase, whereas 
the greater amount  of  the act ivity in the lung decreased 
(data not  shown). The mean concentrat ion per pixel in 
the spleen was 1.5 t imes greater than in the liver al- 
though the total  act ivity in the liver was greater. 
Table 1. Patients and re-transferred LAK cells characteristics 
Patient Age/sex Labelled Viability Labelling 
cells (%) efficacy 
infused (%) 
1 35/m 5 x 10 s > 95 88 
2 69/m 1.6 x 10 s 80 76 
3 76/m 1 x 10 s 75 60 
4 42/m 3 x ]0 s 90 65 
5 54/m 8 x 10 s >_ 95 75 
6 52/m 1.6 x 10 s 94 74 
Table 2. Relative uptake of 111in compared with the contralateral 
side measured scintigraphically 
Patients Tumor Localiza- Relative uptake (%) 
sites tion by 
scintiscan 2.5 24 48 96 p.i. 
1 L lung . . . .  n.d. 
2 R femur + - 1.6 n.d. 1.5 
R axilla + - 1.2 n.d. 1.4 
3 R groin + - 1.5 1.6 n.d. 
4 R axilla + n.d. 1.4 n.d. n.d. 
5 R groin + 1.3 1.55 1.44 n.d. 
6 Sub . . . . .  n.d. 
cutaneous 
- not detectable; n.d., not done; R, right; L, left; p.i., postinfusion 
In four of  six patients,  who underwent  gamma-cam-  
era scint igraphy, images demonst rated  an enr ichment of  
radio label led LAK cells at tumour  sites, including those 
in the lymph nodes, visceral masses and bones, as veri- 
fied by CT or u l trasonic and histological  examinat ion.  
Tumour  detect ion failed in one pat ient  with a single lung 
metastasis  and in another  with subcutaneous tumour  
sites (Table 2). Tumour  visual izat ion was mainly  ob- 
ta ined between 24 and 48 h post- infusion. In only one 
pat ient  was tumour  uptake seen as early as 2.5 h post-  
infusion (Patient 5). The kinetics of  tumour  local isat ion 
in this pat ient  with an inguinal  mass is shown in Fig. 1. 
F igure 2 demonstrates  in another  pat ient  a chain of  in- 
volved lymph nodes extending f rom the scapula to the 
r ight axil la. In one case (Patient 2) tracer uptake at the 
tumour  site increases for at least 4 days. Tumour  imag- 
ing was successful only if the lesions were greater than 
2 cm in diameter.  Radioact iv i ty  rat ios in tumours  com- 
pared with the contra latera l  normal  tissue ranged f rom 
1.2 to 1.6 and were conf i rmed by qual i tat ive observa- 
tions. 
Discussion 
Four  of  six pat ients with metastat ic  mal ignant  melano-  
ma who received 1~ l in_radiolabel le d LAK cells demon-  
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Fig. la-d. Kinetics of tumour localisation on serial scintiscans: a 2.5h, b 24 h, e 48 h post-injection; d right inguinal tumour mass 
imaged by computed tomography 
strated localisation of radioactivity at various tumour 
sites. All sites of increased uptake corresponded to le- 
sions visible on CT scan or ultrasonic examination. The 
failure of tumour homing in our patients with lung and 
subcutaneous metastasis possibly due to the small tu- 
mour size. The best tumour imaging was obtained be- 
tween 24 and 48 h. These late scans suggest recirculation 
of labelled lymphocytes. 
In order to characterize LAK traffic and tumour lo- 
calization, we applied the methods of others who had 
successfully labelled and trafficked normal lymphocytes 
(Lavender et al. 1977; Rannie et al. 1977; Wagstaff et al. 
1981 a). Because of its half-life of 2.8 days, which is long 
enough for in vivo distribution studies, indium 111 is 
the isotope of choice for LAK labelling. Indium 111 ox- 
ine complex offers the advantage of easy penetration 
through cell membranes and binds tightly to cytoplasmic 
proteins; however, the cells have to be suspended in plas- 
ma-free media to protect he indium 111 label from loss 
to plasma transferrin (McAfee and Thakur 1976). Label- 
ling should be limited to 0.4-0.7 MBq/108 cells to avoid 
cellular damage (Chisholm et al. 1979). This condition 
can hardly be fulfilled without leucapheresis (Wagstaff 
et al. 1981a, b). Although there could be reservations 
concerning the detrimental effects of indium 111 label- 
ling on lymphocytes, the increasing accumulation of ac- 
tivity at tumour sites suggests functional integrity of the 
re-transfused cells. 
Ealier imaging studies with radiolabelled autologous 
LAK cells or lectin-activated killer cells failed to demon- 
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Fig. 2a-e. Involved right axillary lymph node chain imaged by 
11 lIn-radiolabelled lymphokine-activated killer cells 24 h after in- 
jection: a right oblique; bventral; e left oblique 
strate consistent uptake at tumour sites. These cells pre- 
ferentially localized to the lung, liver and spleen and 
appeared to be promptly removed from the circulation 
by the reticular-endothelial system. They exhibit the 
same unspecific migration as heat-damaged lymphocytes 
(Lotze et al. 1980; Mazumber et al. 1984; Mukherji et al. 
1988), suggesting that they may have been damaged ur- 
ing labelling or infusion. 
Another possible xplanation of the lack of tumour 
homing in these previous tudies is a suppressive activity, 
which was found in the sources of native IL-2. IL-2 
(T-cell growth factor) used in early human studies was 
obtained from supernatants of peripheral blood mono- 
nuclear cells stimulated with phytohaemagglutinin alo e 
or in combination with phorbol myristate acetate 
(Grimm et al. 1982). These supernatants were generally 
detectinated and partially purified to produce an IL-2- 
enriched fraction, which contains a variety of other fac- 
tors including IL-4. In fact, when this factor was present 
together with IL-2 from the beginning of the culture, 
the lyric activity that normally develops in cultures up- 
plemented with IL-2 alone was almost otally inhibited 
(Widmer et al. 1987). 
The distribution of peripheral blood lymphocytes 
sensitized against autologous tumour cells of various ori- 
gins was studied by Mukherji et al. (1988). He found 
in four of seven patients that sensitized lymphocytes 
showed accumulation at metastatic sites. Only one of 
three patients with metastatic malignant melanoma dem- 
onstrated a positive imaging by injection of LAK cells. 
More recently, Fisher et al. (1989) demonstrated the 
ability of TILs to traffic and localize in tumour sites. 
Six patients with malignant melanoma received cyclo- 
phosphamide 36 h before intravenous TIL infusion fol- 
lowed by IL-2 injection every 8 h. In all patients positive 
tumour imaging was achieved. 
In another study tumour detection failed with 111in - 
labelled TILs with non-specific lytic activity in patients 
with metastatic adenocarcinoma of the lung (Kradin 
et al. 1987). 
Our own results indicate that LAK cells are able 
to migrate to tumour sites. For this phenomenon no 
immunosuppression or additional IL-2 infusion is neces- 
sary. These data confirm the findings of A1 Maghazachi 
et al. (1988) who showed that altering host immunity 
with irradiation, cyclophosphamide an /or administra- 
tion of IL-2 in animals models did not alter the basic 
distribution pattern of LAK cells. 
It is not clear yet whether the anti-tumour effect of 
LAK cells is mediated by indirect effects like induction 
of other cytokines or by direct, cell-mediated cytotoxi- 
city. Tumour homing of LAK cells provides a direct 
interaction between cytotoxic lymphocyte and tumour 
cells which could be an important mechanism for tu- 
mour regression during therapy with IL-2 and LAK 
cells. 
In summary, 111in_labelled LAK cells may be helpful 
for kinetic studies or detection of metastases in patients 
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with malignant melanoma. Further investigations have 
to demonstrate whether LAK cell homing is a prognostic 
factor for immunotherapies u ing IL-2 with or without 
additional cell transfer. 
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